close

Fundraisings and IPOs

Date: 2016-10-12

Type of information: Private placement

Company: Immunomedics (USA - NJ)

Investors:

Amount: $30 million

Funding type: private placement

Planned used:

Immunomedics intends to use the proceeds from the offering primarily in continuing support of clinical and regulatory activities for sacituzumab govitecan - IMMU-132, including submission of a NDA to FDA for accelerated approval in metastatictriple-negative breast cancer, and for working capital and general corporate purposes.

Others:

* On October 12, 2016, Immunomedics announced that it has closed on a previously disclosed underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock, with gross proceeds of $30 million. Each share of common stock and its accompanying warrant was priced
at $3.00. The warrants are exercisable six months following the date of issuance, will expire on the second anniversary of the date of issuance and have an exercise price of $3.75.
* On October 5, 2016, Immunomedics announced that it has priced an underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock with anticipated gross proceeds of $30 million. Each share of common stock and accompanying warrant will be priced at $3.00.
The warrants will be exercisable six months following the date of issuance, will expire on the second anniversary of the date of issuance and have an exercise price of $3.75. Wells Fargo Securities, LLC is acting as sole book-running manager. The closing of the offering is subject to certain customary conditions, and is expected to occur on or about October 11, 2016.
The shares of common stock and accompanying warrants described above are being offered by Immunomedics pursuant to a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission.

Therapeutic area: Cancer - Oncology

Is general: Yes